Search all trials

Find therapies in clinical trials near you – page 47

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 962
countries: 28
conditions: 2 101

3 962 trials recruiting28 European countries2 101 conditions coveredUpdated today

Quick filters

Study Comparing Risankizumab and Ustekinumab for Adults with Moderate to Severe Crohn's Disease After Anti-TNF Therapy Failure

Not recruiting

Registered drugNo placebo

Study Comparing Risankizumab and Ustekinumab for Adults with Moderate to Severe Crohn's Disease After Anti-TNF Therapy Failure

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Risankizumab

Contact Research Centre

Hepatocellular carcinoma

Not recruiting

Registered drugNo placebo

Study of Relatlimab and Nivolumab for Patients with Advanced Liver Cancer Who Have Not Received Immunotherapy After Tyrosine Kinase Inhibitor Treatment

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Nivolumab

Contact Research Centre

Bile duct cancer

Not recruiting

Registered drugNo placebo

Study on Capecitabine and Durvalumab for Patients with Removed Biliary Tract Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Capecitabine

Contact Research Centre

Food allergy

Not recruiting

Registered drug

Study on the Effectiveness and Safety of DBV712 for Peanut Allergy in Children Aged 4-7

Registered drug

France

Participants:0–17 years
Substances:Water For Injection

Contact Research Centre

Breast cancer metastatic

Not recruiting

Registered drugNo placebo

Study on Alpelisib and Fulvestrant or Ribociclib and Fulvestrant for Patients with HR+, HER2- Metastatic Breast Cancer with PIK3CA Mutations

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Alpelisib

Contact Research Centre

Prostate cancer recurrent

Not recruiting

Registered drug

Study Comparing Darolutamide and Androgen Deprivation Therapy to Placebo and Androgen Deprivation Therapy in Men with High-Risk Prostate Cancer Recurrence

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Darolutamide

Contact Research Centre

Oesophageal carcinoma

Not recruiting

Registered drugNo placebo

Study on the Effectiveness and Safety of Pembrolizumab, Lenvatinib, and Chemotherapy for Patients with Metastatic Esophageal Cancer

Registered drugNo placebo

France

Participants:18–64 years · 65+ years
Substances:Cisplatin

Contact Research Centre

Squamous cell carcinoma of head and neck

Not recruiting

Investigational

Study on Radiotherapy with Xevinapant or Placebo for Older Patients with Advanced Head and Neck Cancer

Investigational

France

Participants:65+ years
Substances:Xevinapant

Contact Research Centre

Hepatocellular carcinoma

Not recruiting

Registered drug

Study of Pembrolizumab and Lenvatinib with TACE for Patients with Incurable Non-metastatic Liver Cancer

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Lenvatinib

Contact Research Centre

Endometrial cancer

Not recruiting

Registered drug

Study of Pembrolizumab with Chemotherapy for High-Risk Endometrial Cancer Patients After Surgery

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Anhydrous Docetaxel

Contact Research Centre

Head and neck cancer

Not recruiting

Registered drug

Study of Radiotherapy with Cetuximab and Xevinapant for Patients with Advanced Head and Neck Cancer Unfit for High-Dose Cisplatin

Registered drug

France

Participants:18–64 years · 65+ years
Substances:Cetuximab

Contact Research Centre

Hepatic encephalopathy

Not recruiting

Investigational

Study on Rifaximin for Delaying Hepatic Encephalopathy in Cirrhosis Patients

Investigational

France

Participants:18–64 years · 65+ years
Substances:Rifaximin

Contact Research Centre

Find therapies in clinical trials near you – page 47

583 trials match your criteria

Study Comparing Risankizumab and Ustekinumab for Adults with Moderate to Severe Crohn's Disease After Anti-TNF Therapy Failure

Study Comparing Risankizumab and Ustekinumab for Adults with Moderate to Severe Crohn's Disease After Anti-TNF Therapy Failure

Hepatocellular carcinoma

Study of Relatlimab and Nivolumab for Patients with Advanced Liver Cancer Who Have Not Received Immunotherapy After Tyrosine Kinase Inhibitor Treatment

Bile duct cancer

Study on Capecitabine and Durvalumab for Patients with Removed Biliary Tract Cancer

Food allergy

Study on the Effectiveness and Safety of DBV712 for Peanut Allergy in Children Aged 4-7

Breast cancer metastatic

Study on Alpelisib and Fulvestrant or Ribociclib and Fulvestrant for Patients with HR+, HER2- Metastatic Breast Cancer with PIK3CA Mutations

Prostate cancer recurrent

Study Comparing Darolutamide and Androgen Deprivation Therapy to Placebo and Androgen Deprivation Therapy in Men with High-Risk Prostate Cancer Recurrence

Oesophageal carcinoma

Study on the Effectiveness and Safety of Pembrolizumab, Lenvatinib, and Chemotherapy for Patients with Metastatic Esophageal Cancer

Squamous cell carcinoma of head and neck

Study on Radiotherapy with Xevinapant or Placebo for Older Patients with Advanced Head and Neck Cancer

Hepatocellular carcinoma

Study of Pembrolizumab and Lenvatinib with TACE for Patients with Incurable Non-metastatic Liver Cancer

Endometrial cancer

Study of Pembrolizumab with Chemotherapy for High-Risk Endometrial Cancer Patients After Surgery

Head and neck cancer

Study of Radiotherapy with Cetuximab and Xevinapant for Patients with Advanced Head and Neck Cancer Unfit for High-Dose Cisplatin

Hepatic encephalopathy

Study on Rifaximin for Delaying Hepatic Encephalopathy in Cirrhosis Patients

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.